Aim Immunotech Stock Fundamentals
| AIM Stock | USD 0.23 0.02 9.52% |
AIM ImmunoTech fundamentals help investors to digest information that contributes to AIM ImmunoTech's financial success or failures. It also enables traders to predict the movement of AIM Stock. The fundamental analysis module provides a way to measure AIM ImmunoTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AIM ImmunoTech stock.
At this time, AIM ImmunoTech's Net Interest Income is very stable compared to the past year. As of the 1st of December 2024, Interest Income is likely to grow to about 759.5 K, though Operating Income is likely to grow to (30.3 M). AIM | Select Account or Indicator |
AIM ImmunoTech Company Shares Outstanding Analysis
AIM ImmunoTech's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current AIM ImmunoTech Shares Outstanding | 63.71 M |
Most of AIM ImmunoTech's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AIM ImmunoTech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AIM Shares Outstanding Historical Pattern
Today, most investors in AIM ImmunoTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AIM ImmunoTech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AIM ImmunoTech shares outstanding as a starting point in their analysis.
AIM ImmunoTech Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
AIM Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, AIM ImmunoTech has 63.71 M of shares currently outstending. This is 64.71% lower than that of the Biotechnology sector and 40.38% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 88.86% higher than that of the company.
AIM ImmunoTech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AIM ImmunoTech's current stock value. Our valuation model uses many indicators to compare AIM ImmunoTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AIM ImmunoTech competition to find correlations between indicators driving AIM ImmunoTech's intrinsic value. More Info.AIM ImmunoTech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, AIM ImmunoTech's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value AIM ImmunoTech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.AIM Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AIM ImmunoTech's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics of similar companies.AIM ImmunoTech is currently under evaluation in shares outstanding category among its peers.
AIM Fundamentals
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 10.86 M | ||||
| Shares Outstanding | 63.71 M | ||||
| Shares Owned By Insiders | 8.57 % | ||||
| Shares Owned By Institutions | 14.07 % | ||||
| Number Of Shares Shorted | 491.37 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 5.03 X | ||||
| Price To Sales | 72.93 X | ||||
| Revenue | 202 K | ||||
| Gross Profit | (715 K) | ||||
| EBITDA | (31.68 M) | ||||
| Net Income | (28.96 M) | ||||
| Cash And Equivalents | 27.05 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 718 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (21.27 M) | ||||
| Short Ratio | 1.63 X | ||||
| Earnings Per Share | (0.47) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 26 | ||||
| Beta | -0.36 | ||||
| Market Capitalization | 14.66 M | ||||
| Total Asset | 19.38 M | ||||
| Retained Earnings | (409.51 M) | ||||
| Working Capital | 34.96 M | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 19.38 M |
About AIM ImmunoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -200.7 K | -190.7 K | |
| Total Revenue | 202 K | 386.8 K | |
| Cost Of Revenue | 42 K | 39.9 K | |
| Stock Based Compensation To Revenue | 1.20 | 1.14 | |
| Sales General And Administrative To Revenue | 104.64 | 109.87 | |
| Research And Ddevelopement To Revenue | 54.15 | 56.86 | |
| Capex To Revenue | 2.90 | 3.18 | |
| Ebit Per Revenue | (162.49) | (154.37) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out AIM ImmunoTech Piotroski F Score and AIM ImmunoTech Altman Z Score analysis. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.